Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
CPDM has a team of in vitro/in vivo technicians, bioinformaticians, and scientists offering a wide range of potential collaborations for specific novel method development around cancer modeling or model characterization, including novel assay development.
CPDM welcomes partnering with academia and industry collaborators on method and technology evaluation; we can use cancer models and their associated rich clinical annotations to help validate the application of novel technologies prior to deployment.
Please email us at models@dfci.harvard.edu to explore collaboration ideas.